Evidence map›Paper›PMID 35625800›Full record

ArticleBiomedicines2022

Three-Dimensional Bioprinted Controlled Release Scaffold Containing Mesenchymal Stem/Stromal Lyosecretome for Bone Regeneration: Sterile Manufacturing and In Vitro Biological Efficacy.

Elia Bari, Franca Scocozza, Sara Perteghella, Lorena Segale, Marzio Sorlini, Ferdinando Auricchio, Michele Conti, Maria Luisa Torre

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. The paradigm of stem cell secretome in tissue repair and regeneration: Present and future perspectives.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Elia BariDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy.ORCID 0000-0003-0241-0620
Franca ScocozzaDepartment of Civil Engineering and Architecture, University of Pavia, Via Ferrata 3, 27100 Pavia, Italy.ORCID 0000-0003-0125-3651
Sara PerteghellaDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0003-1128-7636
Lorena SegaleDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy.ORCID 0000-0003-2331-4339
Marzio SorliniPharmaExceed S.r.l., Piazza Castello 19, 27100 Pavia, Italy.
Ferdinando AuricchioDepartment of Civil Engineering and Architecture, University of Pavia, Via Ferrata 3, 27100 Pavia, Italy.ORCID 0000-0002-3735-2400
Michele ContiDepartment of Civil Engineering and Architecture, University of Pavia, Via Ferrata 3, 27100 Pavia, Italy.ORCID 0000-0003-1275-0653
Maria Luisa TorreDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0001-8062-6836
University of Pavia · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Applied Sciences and Arts of Southern Switzerland · CH

Funding

Interreg V-A Italy-Switzerland 2014-2020 ATEx-Advanced Therapies Experiences. Project ID 637541.
6 · The paper itself

Abstract

Recently, 3D-printed scaffolds for the controlled release of mesenchymal stem cell (MSC) freeze-dried secretome (Lyosecretome) have been proposed to enhance scaffold osteoinduction and osteoconduction; coprinting of poly(ε-caprolactone) (PCL) with alginate hydrogels allows adequate mechanical strength to be combined with the modulable kinetics of the active principle release. This study represents the feasibility study for the sterile production of coprinted scaffolds and the proof of concept for their in vitro biological efficacy. Sterile scaffolds were obtained, and Lyosecretome enhanced their colonization by MSCs, sustaining differentiation towards the bone line in an osteogenic medium. Indeed, after 14 days, the amount of mineralized matrix detected by alizarin red was significantly higher for the Lyosecretome scaffolds. The amount of osteocalcin, a specific bone matrix protein, was significantly higher at all the times considered (14 and 28 days) for the Lyosecretome scaffolds. Confocal microscopy further confirmed such results, demonstrating improved osteogenesis with the Lyosecretome scaffolds after 14 and 28 days. Overall, these results prove the role of MSC secretome, coprinted in PCL/alginate scaffolds, in inducing bone regeneration; sterile scaffolds containing MSC secretome are now available for in vivo pre-clinical tests of bone regeneration.

Indexed as

3D coprintingalginate hydrogelbone regenerative medicinebone tissue engineeringLyosecretomemesenchymal stem cellsMSC extracellular vesiclesMSC secretomepoly(ε-caprolactone)

Identifiers

PMID35625800
PMCPMC9138797
OpenAlexW4229054608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.